# BVA-200 vs BVA-100 Validation Study

> **NCT06227819** · — · COMPLETED · sponsor: **Daxor Corporation** · enrollment: 62 (actual)

## Conditions studied

- Heart Failure
- High Blood Pressure
- High Cholesterol
- Anemia
- Diabetes
- Thyroid Diseases
- Kidney Diseases
- Clotting Disorder
- Trauma
- Other Disease

## Interventions

- **DIAGNOSTIC_TEST:** BVA-200

## Key facts

- **NCT ID:** NCT06227819
- **Lead sponsor:** Daxor Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-23
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06227819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06227819, "BVA-200 vs BVA-100 Validation Study". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06227819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*